MC

494

-0.21%↓

SANES

8.24

+0.07%↑

SAF

278.2

-0.22%↓

BBVA

15.775

+0.06%↑

BNP

77.26

+0.63%↑

MC

494

-0.21%↓

SANES

8.24

+0.07%↑

SAF

278.2

-0.22%↓

BBVA

15.775

+0.06%↑

BNP

77.26

+0.63%↑

MC

494

-0.21%↓

SANES

8.24

+0.07%↑

SAF

278.2

-0.22%↓

BBVA

15.775

+0.06%↑

BNP

77.26

+0.63%↑

MC

494

-0.21%↓

SANES

8.24

+0.07%↑

SAF

278.2

-0.22%↓

BBVA

15.775

+0.06%↑

BNP

77.26

+0.63%↑

MC

494

-0.21%↓

SANES

8.24

+0.07%↑

SAF

278.2

-0.22%↓

BBVA

15.775

+0.06%↑

BNP

77.26

+0.63%↑

Search

Bayer AG

Open

BrancheFinanzen

28.06 0.5

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

27.665

Max

28.325

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.5B

-190M

Verkäufe

-3B

11B

KGV

Branchendurchschnitt

30.9

27.32

EPS

1.23

Dividendenrendite

0.39

Gewinnspanne

-1.769

Angestellte

89,556

EBITDA

-3.4B

236M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-0.28% downside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.39%

3.64%

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

359M

27B

Vorheriger Eröffnungskurs

27.56

Vorheriger Schlusskurs

28.06

Nachrichtenstimmung

By Acuity

29%

71%

110 / 531 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Bayer AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2025, 06:18 UTC

Ergebnisse

Bayer Loss Widens on Litigation Charges

13. Mai 2025, 08:22 UTC

Ergebnisse
Wichtige Markttreiber

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13. Mai 2025, 06:09 UTC

Ergebnisse

Bayer Confirms Guidance Despite Net Profit Drop

6. Aug. 2025, 15:01 UTC

Market Talk
Ergebnisse

Bayer Expects Bumper U.S. Crop -- Market Talk

6. Aug. 2025, 14:52 UTC

Market Talk

Bayer says Litigation Situation With Roundup 'Unsustainable' -- Market Talk

6. Aug. 2025, 09:05 UTC

Market Talk

Bayer Expects Weedkiller Dicamba Back on U.S. Market in 2026 -- Market Talk

6. Aug. 2025, 07:27 UTC

Market Talk
Ergebnisse

Bayer's Results Deliver Few Surprises -- Market Talk

6. Aug. 2025, 05:43 UTC

Ergebnisse

Bayer: Crop Science Division Now in a Position to Streamline Production and Operations

6. Aug. 2025, 05:43 UTC

Ergebnisse

Bayer: Making Headway on Plan to Improve Profitability in Agricultural Business

6. Aug. 2025, 05:42 UTC

Ergebnisse

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

6. Aug. 2025, 05:41 UTC

Ergebnisse

Bayer Expects Significant Currency Fluctuations With Headwinds on Sales and Profits, Favorable Effects on Debt

6. Aug. 2025, 05:41 UTC

Ergebnisse

Bayer: 2H Will Be Marked by Progress on Strategic Priorities, Launches, Geopolitical and Currency Crosswinds

6. Aug. 2025, 05:33 UTC

Ergebnisse

Bayer 2Q Net Loss EUR199M

6. Aug. 2025, 05:32 UTC

Ergebnisse

Bayer Had Pre-Announced 2Q Ebitda Before Special Items at EUR2.1B

6. Aug. 2025, 05:32 UTC

Ergebnisse

Bayer 2Q Ebitda Before Special Items EUR2.11B

6. Aug. 2025, 05:32 UTC

Ergebnisse

Bayer Had Pre-Announced 2Q Sales at EUR10.7B

6. Aug. 2025, 05:32 UTC

Ergebnisse

Bayer 2Q Sales EUR10.74B

30. Juni 2025, 15:09 UTC

Market Talk

Supreme Court Asks for Government's View on Bayer's Roundup Case -- Market Talk

5. Juni 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30. Mai 2025, 13:47 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27. Mai 2025, 12:22 UTC

Market Talk
Ergebnisse

Bayer's Prospects Are Improving -- Market Talk

16. Mai 2025, 13:42 UTC

Heiße Aktien

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16. Mai 2025, 08:57 UTC

Heiße Aktien

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13. Mai 2025, 06:50 UTC

Market Talk
Ergebnisse

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13. Mai 2025, 05:36 UTC

Ergebnisse

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13. Mai 2025, 05:35 UTC

Ergebnisse

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

Peer-Vergleich

Kursveränderung

Bayer AG Prognose

Kursziel

By TipRanks

-0.28% Nachteil

12-Monats-Prognose

Durchschnitt 28.08 EUR  -0.28%

Hoch 35 EUR

Tief 23 EUR

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bayer AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

4

Buy

9

Halten

0

Sell

Technischer Score

By Trading Central

22.99 / 23.88Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

110 / 531 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat